Objective-To evaluate the prognostic significance of plasma N-terminal proatrial natriuretic factor (1-98) concentrations measured in the subacute phase after acute myocardial infarction, and to compare the predictive value of measurement of N-terminal pro-atrial natriuretic factor (1-98) with the measurement of atrial natriuretic factor and clinical assessment of heart failure (N-terminal pro-atrial natriuretic factor (1-98), p = 0 0003; atrial natriuretic factor (99-126), p = 0-4513; heart failure, p = 0*0719). The odds ratio estimate of patients in whom plasma concentrations of N-terminal pro-atrial natriuretic factor (1-98) were greater than 2000 pmolIl was 25 (95% confidence interval 2-8-225.0) compared with patients with plasma concentrations less than 1000 pmolll.
myocardial infarction. Patients in cardiogenic shock or with severe heart failure (New York Heart Association class IV) were excluded. Main outcome measure-Cardiovascular death within 12 months. Results-During the follow up period 15 patients died. In a univariate Cox proportional hazards model N-terminal pro-atrial natriuretic factor (1-98) was significantly related to mortality (p = 0.0003). In a multivariate model the prognostic value of N-terminal pro-atrial natriuretic factor (1-98) was better than that of atrial natriuretic factor and clinical assessment of heart failure (N-terminal pro-atrial natriuretic factor (1-98), p = 0 0003; atrial natriuretic factor (99-126), p = 0-4513; heart failure, p = 0*0719). The odds ratio estimate of patients in whom plasma concentrations of N-terminal pro-atrial natriuretic factor (1-98) were greater than 2000 pmolIl was 25 (95% confidence interval 2-8-225.0) compared with patients with plasma concentrations less than 1000 pmolll.
Conclusions-These results suggest that determination of plasma N-terminal proatrial natriuretic factor (1-98) in the subacute phase of myocardial infarction may provide clinically relevant prognostic information that is superior to that obtained from atrial natriuretic factor (99-126) measurements and clinical evaluation.
(Br Heart _r 1993;70:409-414) Atrial natriuretic factor is derived from a 126 amino acid prohormone synthesised and stored in secretory granules in the atrial cardiocytes.' Until now research has focused mainly on the physiological and pathophysiological role of the atrial natriuretic factor (99-126) in cardiovascular and renal homoeostasis: only recently has the N-terminal fragment of the prohormone of atrial natriuretic factor been identified as a peptide in human plasma,23 circulating predominantly as a single, high molecular weight form (pro-atrial natriuretic factor (1-98)). 4 Though the role of N-terminal pro-atrial natriuretic factor (1-98) in cardiovascular homoeostasis has not yet been clearly defined, raised plasma concentrations have been detected during exercise56 and in patients with essential hypertension,' myocardial infarction,8 and cardiac and renal failure.2 6 79 Many data indicate that atrial natriuretic factor (99-126) is a marker of cardiac function. Significant correlations between plasma concentrations of the peptide and haemodynamic indices have been demonstrated in chronic heart failure'1"3 and in myocardial infarction.'415 Recently it has also become evident that measurement of atrial natriuretic factor (99-126) may provide valuable prognostic information in chronic heart failure '6 17 as well as in acute myocardial infarction. 18 The prognostic significance of N-terminal pro-atrial natriuretic factor (1-98), however, remains to be established.
Consequently, the main objectives of the present study were to evaluate the prognostic information obtained by the determination of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction and to compare the predictive value of N-terminal pro-atrial natriuretic factor (1-98) with that of atrial natriuretic factor (99-126). Furthermore, we used a multivariate Cox proportional hazards model to establish whether plasma N-terminal pro-atrial natriuretic factor (1-98) and atrial natriuretic factor (99-126) concentrations measured soon after infarction provide additional prognostic information to that obtained by in-hospital clinical assessment of cardiac impairment. Blood samples for analysis of N-terminal pro-atrial natriuretic factor (1-98) were collected from 139 patients with acute myocardial infarction who were followed for one year for survival analysis.
Patients and methods

STUDY DESIGN
The randomised placebo controlled double blind Cooperative New Enalapril Scandinavian Survival Study (CONSENSUS II) studied the effect on mortality of enalapril administered within 24 hours after the onset of symptoms in patients with acute myocardial infarction.'9 Our substudy was designed to evaluate the prognostic value of N-terminal pro-atrial natriuretic factor (1-98) concentration in acute myocardial infarction.
The diagnosis of myocardial infarction was based on the combination of chest pain lasting >20 minutes and standard electrocardiographic criteria compatible with infarction or enzymatic evidence of myocardial necrosis. Exclusion criteria included supine systolic blood pressure <100 mm Hg or diastolic blood pressure <60 mm Hg, cardiogenic shock or the need for pressor support, haemodynamically significant valvar stenosis, or severe congestive heart failure (New York Heart Association class IV).
Throughout their hospital stay patients were regularly examined and their clinical status recorded. Clinical heart failure was defined as pulmonary congestion warranting treatment with diuretics. 
Results
During the one year follow up period 16 patients died. One of these patients died of a non-cardiovascular cause on day 94 after myocardial infarction and was subsequently censored from the analysis. Figure 1 shows the distribution of individual plasma concentrations of N-terminal pro-atrial natriuretic factor (1-98) in those who were alive at 1 year and in those who were dead. There were six deaths in the group of patients originally randomised to enalapril and nine in the original placebo group.
The concentration of N-terminal pro-atrial natriuretic factor (1-98) on day 3 was 1603 (133) pmol/l (median 1241 pmol/l), while the mean concentration of plasma atrial natri- uretic factor (99-126) on day 3 was 36-1 (2-2) pmol/l. The correlation between plasma concentrations of N-terminal pro-atrial natriuretic factor (1-98) and atrial natriuretic factor (99-126) (r = 0-81, p < 0O001) was good (fig 2) . Serum creatinine concentrations at admission correlated significantly with day 3 plasma concentrations of N-terminal proatrial natriuretic factor (1-98) (n = 123, r = 0-53; p < 0-001). There was no significant difference in day 3 plasma N-terminal proatrial natriuretic factor concentrations between the enalapril and the placebo group (1439 (146) v 1774 (224) pmol/l, p = 0-233). In a multivariate model, treatment with diuretics and lack of thrombolytic therapy during the in-hospital phase were associated with higher plasma concentrations of N-terminal pro-atrial natriuretic factor (1-98) (diuretics, p = 0 005; thrombolytic therapy, p = 0-043; r2 = 0.09). In contrast, treatment with converting enzyme inhibitors or ,B adrenoceptor blockers had no evident effect on concentrations.
The plasma concentration of N-terminal pro-atrial natriuretic factor (1-98) was significantly related to mortality in a univariate Cox proportional hazards regression model (p = 0 0003). Atrial natriuretic factor (99-126) and clinical heart failure were also significantly related to survival in univariate analysis (atrial natriuretic factor (99-126), p = 0 0004; heart failure, p = 0-0010). There was no significant relation between age (p = 0<1536), heart rate (p = 0 4039), or systolic blood pressure (p = 0-4544) and mortality (table 1) . In a multivariate model only N-terminal pro-atrial natriuretic factor (1-98) provided independent prognostic information (table 1).
Furthermore, division of patients into two groups according to the upper normal limit of the plasma concentration of pro-atrial natriuretic factor (1-98) (1100 pmol/l) showed that mortality was significantly higher in the group with raised concentrations of N-terminal pro-atrial natriuretic factor (1-98) (13 Omland, Bonarlee, Nilsen, Sundsfiord, Lie, Thibault, Dickstein Table 3 One year mortality by the concentration of N-terminal pro-atrial natriuretic factor (1-98) in plasma Plasma ANF (1-98) (pmol/l) patients) than in the patients with values within the normal range (two patients) (p = 0-026) (fig 3) . Table 2 compares the demographic, clinical, and biochemical variables in patients with high concentrations of N-terminal pro-atrial natriuretic factor (1-98) and patients with low concentrations. Logistic regression analysis showed that the odds ratio of patients with plasma concentrations of N-terminal pro-atrial natriuretic factor (1-98) > 2000 pmolIl was 25-0 (95% confidence interval 2-8 to 225-0) compared with an odds ratio of 1 0 in patients with plasma concentrations <1000 pmol/l (table   3 ). Figure 4 shows the estimated probability of cardiac death within 1 year as a function of plasma N-terminal pro-atrial natriuretic factor (1-98) according to a discriminant analysis model. The discriminant model showed that the optimal cut-off value for pro-atrial natriuretic factor (1-98) to divide patients into a high risk group and a low risk group was 1648 pmol/l. This cut-off value gave a sensitivity of 53-3% (false negative rate 47-7%) and a specificity of 79-8% (false positive rate 20-2%). The corresponding positive and negative predictive values were 24-2% and 93-4%, respectively. The arbitrary cut-off value of 1100 pmolIl gave a sensitivity of 86-7% (false negative rate 13-3%) and a specificity of 43-5%) (false positive rate 56-5%) for prediction of one year mortality (positive predictive value 15-7%, negative predictive value 96-4%).
Discussion
Our data confirm and extend current knowledge of the prognostic significance of atrial natriuretic factor in cardiac disease. Though both the presence of clinical heart failure and the plasma concentration of atrial natriuretic factor (99-126) were related to mortality in the univariate analysis, the addition of these two factors to the multivariate Cox model did not improve the prognostic information compared with the information provided by Nterminal pro-atrial natriuretic factor (1-98) determination alone.
Atrial natriuretic factor (99-126) and mortality were related in patients with chronic cardiac failure'6 17 and in patients with acute myocardial infarction.'8 However, the instability of atrial natriuretic factor (99-126) (plasma half life <3 minutes)25 and the timeconsuming and cumbersome method of detection tend to limit the clinical usefulness of such measurements. In contrast, the plasma half-life of the N-terminal pro-atrial natriuretic factor (1-98) fragment is approximately one hour,26 and incubation of samples at room temperature for up to 24 hours did not significantly reduce the plasma concentration.2 Further, direct assay of the N-terminal pro-atrial natriuretic factor (1-98) fragment without prior extraction is feasible and simplifies the analysis.2 The significant relation that we found between subacute plasma concentrations of N-terminal proatrial natriuretic factor (1-98) and 1-year mortality after acute myocardial infarction may thus be clinically important.
The relation between the plasma concentration of N-terminal pro-atrial natriuretic factor and mortality after acute myocardial infarction is not likely to be causal. Infusion studies in healthy individuals,27 in patients with chronic heart failure28 and myocardial infarction29 all indicate that atrial natriuretic factor (99-126) has beneficial, albeit weak, physiological actions. Furthermore, intravenous administration of the endopeptidase inhibitor candoxatrilat, which inhibits the degradation of atrial natriuretic factor (99-126), had beneficial haemodynamic and natriuretic effects in patients with severe chronic heart failure. 30% of eligible patients, we studied more than 60% of patients admitted to our coronary care unit during the six months recruitment period. Furthermore, our sample may be more representative of the general myocardial infarction population because patients were included irrespective of concurrent therapy, whereas patients receiving cardiovascular drugs before blood sampling were excluded from the Danish study.'8 Though we excluded patients with severe heart failure and patients in cardiogenic shock, we believe that this tends to underestimate rather than overestimate the relation between atrial natriuretic factor and prognosis, because both groups have markedly increased plasma concentrations of atrial natriuretic factor and a poor prognosis.38 The choice of day 3 after myocardial infarction as the time for blood sampling was arbitrary, but it coincides with peak plasma concentrations of atrial natriuretic factor in most previous reports39 40 and has the advantage of being performed during daytime and after haemodynamic stabilisation of the patient.
The patients with plasma concentrations N-terminal pro-atrial natriuretic factor (1-98) greater than 1100 pmolIl were significantly older than those with a value less than 1100 pmol/l. This observation might contribute to the association between N-terminal pro-atrial natriuretic factor and mortality. However, though there was a positive relation between the plasma concentration of N-terminal pro-atrial natriuretic factor and age (r = 0.34, p < 0-001), adjustment for age in the Cox proportional hazards model did not alter the relation between N-terminal pro-atrial natriuretic factor (1-98) and survival.
In conclusion, these results suggest that the measurement of plasma concentrations of Nterminal pro-atrial natriuretic factor (1-98) may provide a readily obtainable prognostic index in acute myocardial infarction that is superior to that obtained from atrial natriuretic factor (99-126) measurements and risk stratification according to the presence of symptomatic ventricular impairment. The prognostic value of N-terminal pro-atrial natriuretic factor (1-98) is emphasised by the fact that its significance is evident despite the presence of various factors that can affect plasma concentrations of the peptide-for example, concurrent medical treatment, renal function, and sodium intake. Further, because the greater stability and subsequent increase in plasma concentrations simplifies analysis, assessment of the N-terminal proatrial natriuretic factor (1-98) may prove to be more versatile than measuring the atrial natriuretic factor (99-126) fragment. Whether measurement of plasma N-terminal pro-atrial natriuretic factor (1-98) is a better indicator of outcome than echocardiographic and haemodynamic indices of cardiac performance remains to be determined.
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